Annotation of CYP2D6 intermediate metabolizer

CYP2D6 intermediate metabolizer is associated with increased likelihood of Nausea, Headache, insomnia or Drug Toxicity when exposed to mirabegron in healthy individuals as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.

"Headache was the most common ADR (9 times), followed by nausea (3 times), vomiting (2 times), loose stool, palpitations and insomnia (1 time each). ""CYP2D6 IMs showed a higher ADR incidence (37.5%) than NMs (5.5%) and UMs (0%) (puv = 0.008, pmv = 0.010, OR = 9.83)."

Gene

CYP2D6

Phenotype Category

Toxicity

Association Significance

The study reports this association is significant

PharmGKB ID

1452574551

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

    Study Parameters

    Study type

    clinical trial

    Study size

    75

    Association p-value

    = 0.010

    Biogeographical group
    More info on groups

    Multiple groups, Origin "European" and "Latin American"

    Country

    Spain

    Population description

    men; women; healthy individuals

    Study Cohort: ADR

    Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

    History

    Loading...